Krause T, Fleming A, Hurst M, Zema C, Costello J, Hawe E, Ling C. Prognostic factors and surrogate endpoints in obstructive hypertrophic cardiomyopathy: a systematic literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S36. doi: 10.1016/j.jval.2023.09.189
Houghton K, Nangia A, Hawe E. Use of external control arms (ECAs) in marketing applications submitted to European medicines agency (EMA): a targeted review. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S404. doi: 10.1016/j.jval.2023.09.2119
Nangia A, Houghton K, Hawe E. Use of external control arms in pharmaceutical submissions to the national institute for health and care excellence for technology appraisals: a targeted review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S416. doi: 10.1016/j.jval.2023.09.2180
Hawe E, Simou E, Balp MM, Kohli R, Wiyani A. Influence of disease activity and angioedema on EQ-5D-5L utility scores in chronic spontaneous urticaria. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S500. doi: 10.1016/j.jval.2023.09.2697
Kamgar F, Ho S, Hawe E, Brodtkorb TH. A review of treatment effect waning methods for immuno-oncology therapies in National Institute for Health and Care Excellence technology appraisals. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S98. doi: 10.1016/j.jval.2022.09.476
Yucel E, Hartley L, Bell J, Wolowacz S, Kamgar F, Hawe E. A systematic literature review of utility estimates for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S395. doi: 10.1016/j.jval.2022.09.1964
Yucel E, Lunan M, Hartley L, Ahdesmaki O, Bull R, Hawe E. A systematic literature review of prognostic factors and surrogate endpoint analyses in chronic lymphocytic leukemia and small lymphocytic lymphoma. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S35. doi: 10.1016/j.jval.2022.09.169
Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Petrillo Billet J. Driving outcomes in mild cognitive impairment/Alzheimer's disease - a review of association between driving simulator measures and clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Billet JP. Impact of Huntington's disease on driving: a review of driving simulator measures and association with clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Hartley L, Harold S, Hawe E. A systematic review of the efficacy, safety and immunogenicity of plague vaccines. Poster presented at the ISPOR 2022 Conference; May 16, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Jen MH, Sonksen M, Kiiskinen U, Wolowacz S, Vickers AD, Hawe E. Surrogate outcomes for overall survival in pretreated non-small cell lung cancer: expanding the prediction range. Poster presented at the Virtual ISPOR Europe 2021; December 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.
Aronsson M, Dunton K, Hawe E, Wolowacz S, Quoraishi S, Durrington P, Ray KK, Bilitou A. Building a cost-effectiveness MODEL framework from a payer's perspective to assess NOVEL treatments in primary hypercholesterolaemia and MIXED dyslipidaemia: challenges in a world of LDL-C lowering. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Zuluaga S, Hess LM, Wolowacz S, Dyachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for the treatment of locally advanced or metastatic soft tissue sarcoma in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A108.
Bertwistle D, D'Yachkova Y, Vickers AD, Hawe E, Fernandez M, Drove N, Lorenzo M, Wolowacz S. Comparative efficacy and saftey of interventions in the treatment of advanced soft tissue sarcoma: a systematic review and network meta analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A712.